JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groudine, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Groudine, S.

Anesth Analg 2007;105:884
© 2007 International Anesthesia Research Society
doi: 10.1213/01.ane.0000269686.43286.0d


LETTER TO THE EDITOR

Section Editor:
Lawrence Saidman

Sugammadex–Rocuronium Dosing

Scott Groudine, MD

Department of Anesthesiology; Albany Medical Center; Albany, NY

In Response:

A dose of sugammadex that cannot bind all the available rocuronium will most certainly be inadequate. As an example, De Boer et al. (1) were unable to alter the duration of rocuronium in the monkey when a 1 mg/kg dose of sugammadex was given 1 min after 0.5 mg/kg of rocuronium. Increasing the dose to 2.5 mg/kg (40% greater than the equimolar dose of rocuronium) decreased the duration of the rocuronium block but had a prolonged onset.

The calculated equimolar dose of sugammadex is the theoretical minimum required to reverse a recently induced rocuronium block. After injection, some sugammadex will bind other steroids or be renally excreted. Therefore, some multiple of the equimolar dose will be required to fully reverse the effect of rocuronium and this multiple will have to be even greater for rapid onset. The calculated equimolar dose of sugammadex is not the same as a clinically effective dose. This will always be greater. Dr. Kopman's skepticism of the efficacy of basing clinical dosing on the calculated equimolar dose is entirely warranted. I thank Dr. Kopman (2) for his thoughtful comments on our study (3).

REFERENCES

  1. De Boer H, van Egmond J, van de Pol F, Bom A, Booij LHDJ. Reversal of profound neuromuscular blockade by sugammadex in anesthetized rhesus monkeys. Anesthesiology 2006;104:718–23[Web of Science][Medline]
  2. Kopman AF. Sugammadex-rocuronium dosing. Anesth Analg 2007;105:883–4[Free Full Text]
  3. Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 2007;104:555–62[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Anesth. Analg.Home page
K. W. Hatton and B. G. Fahy
Vagal Nerve Stimulation and Reflux
Anesth. Analg., September 1, 2007; 105(3): 885 - 885.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groudine, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Groudine, S.


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2007 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press